Neuren Pharmaceuticals Ltd
ASX:NEU

Watchlist Manager
Neuren Pharmaceuticals Ltd Logo
Neuren Pharmaceuticals Ltd
ASX:NEU
Watchlist
Price: 18.17 AUD 0.66% Market Closed
Market Cap: 2.3B AUD

Intrinsic Value

The intrinsic value of one NEU stock under the Base Case scenario is hidden AUD. Compared to the current market price of 18.17 AUD, Neuren Pharmaceuticals Ltd is hidden .

NEU Intrinsic Value
HIDDEN
Show
Base Case Scenario

Valuation History
Neuren Pharmaceuticals Ltd

Intrinsic Value History
Dive into the past to invest in the future

NEU looks overvalued. Yet it might still be cheap by its own standards. Some stocks live permanently above intrinsic value; Historical Valuation reveals whether NEU usually does or if today's premium is unusual.

Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Show Historical Valuation
What is Valuation History?
Ask AI Assistant
What other research platforms think about NEU?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is NEU valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Neuren Pharmaceuticals Ltd.

Explain Valuation
Compare NEU to
Custom
Choose any stock to compare

Fundamental Analysis

NEU Profitability Score
Profitability Due Diligence

Loading...
Loading...
Loading...
Loading...
Profitability
Score

NEU Solvency Score
Solvency Due Diligence

Loading...
Loading...
Loading...
Loading...
Solvency
Score
Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Regulatory uncertainty surrounding Neuren’s lead candidate trofinetide—particularly in complex neurological indications—poses a significant risk, as any delays in approvals or unfavorable trial data could derail the company’s revenue timeline and shake investor confidence.

Bull Theses

Trofinetide’s potential first-mover advantage in Rett syndrome offers a pathway to regulatory approval and commercial success, creating a strong, near-term revenue stream if upcoming data and launches proceed favorably.

Show More Less
How do you feel about NEU?
Bearish
Neutral
Bullish
Efficiency

Free Cash Flow Analysis
Neuren Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Wall St
Price Targets

NEU Price Targets Summary
Neuren Pharmaceuticals Ltd

Wall Street analysts forecast NEU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NEU is 25.46 AUD with a low forecast of 21.41 AUD and a high forecast of 32.03 AUD.

Lowest
Price Target
21.41 AUD
18% Upside
Average
Price Target
25.46 AUD
40% Upside
Highest
Price Target
32.03 AUD
76% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Neuren Pharmaceuticals Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for NEU is hidden .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
HIDDEN
Show
Dividend Yield
No dividends
Buyback Yield
HIDDEN
Debt Paydown Yield
HIDDEN

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one NEU stock?

The intrinsic value of one NEU stock under the Base Case scenario is hidden AUD.

Is NEU stock undervalued or overvalued?

Compared to the current market price of 18.17 AUD, Neuren Pharmaceuticals Ltd is hidden .

Back to Top